Studies evaluating larger cohorts of cancers by immunohistochemistry (IHC) have identified associations between high AGR2 expression and unfavorable tumor phenotype or poor prognosis in adenocarcinoma of the lung [10], gastric adenocarcinoma [22], and adenocarcinoma of the prostate [23]. Here, AGR2 is linked to lung adenocarcinoma.